Alert: FDA Accelerates Psilocybin & Methylone Drug Review with Priority Vouchers

The FDA has awarded three Commissioner’s National Priority Vouchers (CNPVs) to Compass Pathways (psilocybin for TRD), Usona Institute (psilocybin for MDD), and Otsuka/Transcend (methylone for PTSD). These vouchers are designed to significantly reduce the new drug application (NDA) review period to just one to two months, signaling an accelerated path to market for these substances. This move underscores the FDA's commitment to advancing psychedelic therapies, with further guidance for sponsors expected imminently.